Press Release Archive

 
09.09.2021 - UK’s MHRA Grants Marketing Authorisation for Pfizer’s CIBINQO® (abrocitinib) for Adults and Adolescents With Moderate to Severe Atopic Dermatitis
*/ /*-->*/ /*-->*/

-Abrocitinib is a once-daily oral JAK1 inhibitor indicated in Great Britain for the treatment of moderate to severe atopic dermatitis in patients aged 12 years and over, who are candidates for systemic therapy-

-This is the first marketing authorization globally for abrocitinib-

 
09.07.2021 - Pfizer Invites Public to Listen to Two Webcasts of Pfizer Discussions at Upcoming Healthcare Conferences
*/ /*-->*/ /*-->*/

NEW YORK--(BUSINESS WIRE)-- Pfizer Inc. (NYSE: PFE) invites investors and the general public to listen to two webcasts of discussions with Pfizer executives at two upcoming healthcare conferences.

 
09.02.2021 - Pfizer Announces Start of Phase 3 Clinical Trial in Adults for Its Investigational Vaccine Against Respiratory Syncytial Virus (RSV)
*/ /*-->*/ /*-->*/
  • First subjects vaccinated in study of Pfizer’s RSV bivalent prefusion F subunit investigational vaccine candidate in adults ages 60 or older
  • RSV is a common and pervasive cause of severe acute respiratory illness in
 
08.30.2021 - Positive Top-Line Results From Pfizer’s Phase 3 JADE DARE Trial Comparing the Efficacy of Abrocitinib and Dupilumab for Moderate to Severe Atopic Dermatitis
*/ /*-->*/ /*-->*/

-JADE DARE trial met co-primary and key secondary endpoints and demonstrated a safety profile consistent with previous studies-

 
08.26.2021 - Pfizer Announces New Chief Business Innovation Officer
*/ /*-->*/ /*-->*/

NEW YORK--(BUSINESS WIRE)-- Pfizer Inc. (NYSE: PFE) today announced that Aamir Malik has joined the company as Executive Vice President and Chief Business Innovation Officer. Mr. Malik will be a member of Pfizer’s Executive Leadership Team reporting to Chairman and Chief Executive Officer, Albert Bourla. Mr.

 
08.26.2021 - Pfizer and BioNTech Announce Collaboration With Brazil’s Eurofarma to Manufacture COVID-19 Vaccine Doses for Latin America
*/ /*-->*/ /*-->*/

NEW YORK & MAINZ, Germany--(BUSINESS WIRE)-- Pfizer Inc.

 
08.25.2021 - Pfizer and BioNTech Initiate Rolling Submission of Supplemental Biologics License Application to U.S. FDA for Booster Dose of COMIRNATY® in Individuals 16 and Older
*/ /*-->*/ /*-->*/
  • New Phase 3 data show booster (third) dose of COMIRNATY induces significant SARS-CoV-2 neutralizing antibody titers and demonstrated a favorable safety and tolerability profile
 
08.23.2021 - Pfizer-BioNTech COVID-19 Vaccine COMIRNATY® Receives Full U.S. FDA Approval for Individuals 16 Years and Older
*/ /*-->*/ /*-->*/
  • COMIRNATY is the first COVID-19 vaccine to be granted FDA approval
  • Approval is based on a comprehensive submission package including six-month efficacy and safe
 
08.23.2021 - Pfizer to Acquire Trillium Therapeutics Inc.
*/ /*-->*/ /*-->*/

Proposed acquisition strengthens Pfizer’s category leadership in Oncology with addition of next-generation, investigational immuno-therapeutics for hematological malignancies

 
08.16.2021 - Pfizer Prices $1.0 Billion Sustainability Bond
*/ /*-->*/ /*-->*/

NEW YORK--(BUSINESS WIRE)-- Pfizer Inc. (NYSE: PFE) today announced the pricing of a sustainability bond of $1,000,000,000 in aggregate principal amount of 1.750% senior notes due 2031.

 
08.16.2021 - Pfizer and BioNTech Announce Submission of Initial Data to U.S. FDA to Support Booster Dose of COVID-19 Vaccine
*/ /*-->*/ /*-->*/
  • Phase 1 safety and immunogenicity data in individuals who received a third dose of the Pfizer-BioNTech vaccine (BNT162b2) show a favorable safety profile and robust immune responses
  • The booster dose elicited signi
 
08.13.2021 - U.S. FDA Approves TICOVAC™, Pfizer’s Tick-Borne Encephalitis (TBE) Vaccine
*/ /*-->*/ /*-->*/

TICOVAC™ may help reduce the risk of TBE for people traveling to endemic areas, potentially including military personnel serving in these locations

 
08.12.2021 - VTX-801 Receives U.S. FDA Fast Track Designation for the Treatment of Wilson Disease

Paris, France and New York, NY, August 12, 2021 – Vivet Therapeutics (“Vivet”), a clinical-stage biotechnology company, and Pfizer Inc. (NYSE: PFE) today announced the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to VTX-801, Vivet’s clinical-stage gene therapy for the treatment of Wilson Disease – a rare, genetic disorder that reduces the ability of the liver and other tissues to regulate copper levels, causing severe hepatic damage, neurological symptoms, and potentially death.

 
08.04.2021 - Pfizer Announces Positive Top-Line Results from Phase 2b/3 Trial of Ritlecitinib in Alopecia Areata
*/ /*-->*/ /*-->*/

ALLEGRO 2b/3 trial met primary efficacy endpoint of improving scalp hair regrowth –

 
07.23.2021 - Pfizer and BioNTech to Provide U.S. Government with an Additional 200 Million Doses of COVID-19 Vaccine to Help Meet Continued Need for Vaccine Supply in the U.S.
*/ /*-->*/ /*-->*/

Dose deliveries for new order expected to occur from October 2021 through April 2022

 
07.22.2021 - Arvinas and Pfizer Announce Global Collaboration to Develop and Commercialize PROTAC® Protein Degrader ARV-471

– Collaboration combines Arvinas’ investigational estrogen receptor-targeting breast cancer therapy with Pfizer’s deep experience in breast oncology therapeutics –
– ARV-471 is currently in Phase 2 development for the treatment of patients with locally advanced or metastatic ER+/HER2- breast cancer –
– Arvinas to receive $650 million in an upfront payment, in addition to a potential $1.4 billion in milestone payments; profits and costs to be shared 50/50 worldwide –
– Pfizer to complete a $350 million equity investment in Arvinas –

 
07.21.2021 - Pfizer Provides Update on U.S. FDA Review of Abrocitinib and XELJANZ® Filings
*/ /*-->*/ /*-->*/

NEW YORK--(BUSINESS WIRE)-- Pfizer Inc. (NYSE: PFE) announced today that the U.S.

 
07.21.2021 - Pfizer and BioNTech Announce Collaboration With Biovac to Manufacture and Distribute COVID-19 Vaccine Doses Within Africa
*/ /*-->*/ /*-->*/

NEW YORK & MAINZ, Germany--(BUSINESS WIRE)-- Pfizer Inc.

Note: These press releases were issued in the United States and are intended as reference information for U.S. investors and journalists. The information contained in each press release was accurate at the time of issuance, and Pfizer assumes no responsibility for updating the information to reflect subsequent developments.